Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
CIKN/A
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.12 million
Profitability
Miscellaneous
Employees291
Next Earnings Date5/9/2019 (Confirmed)
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) announced its earnings results on Tuesday, March, 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The business had revenue of $4.24 million for the quarter, compared to analysts' expectations of $6.70 million. Cronos Group had a negative net margin of 120.65% and a negative return on equity of 9.50%. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
10 Wall Street analysts have issued 1 year price objectives for Cronos Group's shares. Their forecasts range from $13.00 to $30.00. On average, they expect Cronos Group's stock price to reach $21.0860 in the next year. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 4 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
Media coverage about CRON stock has trended positive on Saturday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cronos Group earned a news impact score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Are investors shorting Cronos Group?
Cronos Group saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 23,550,475 shares, an increase of 24.9% from the March 15th total of 18,853,390 shares. Based on an average daily trading volume, of 10,614,785 shares, the short-interest ratio is currently 2.2 days. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Tilray (TLRY), USANA Health Sciences (USNA), CV Sciences (CVSI), Chromadex (CDXC), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), Cyanotech (CYAN), GLG Life Tech (GLGLF) and Tauriga Sciences (TAUG).
What other stocks do shareholders of Cronos Group own?
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.07%), Wedbush Securities Inc. (0.04%), Pennsylvania Trust Co (0.03%), Pennsylvania Trust Co (0.03%), Toth Financial Advisory Corp (0.01%) and Dubuque Bank & Trust Co. (0.01%).
Which major investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd..
Which major investors are buying Cronos Group stock?
CRON stock was acquired by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Pennsylvania Trust Co, Virtu Financial LLC, Toth Financial Advisory Corp, Dubuque Bank & Trust Co., Wedbush Securities Inc., Liberty Wealth Management LLC and Asset Dedication LLC.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $15.75.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.81 billion and generates $12.12 million in revenue each year. The company earns $-14,640,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Cronos Group employs 291 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
